Alexander R Opotowsky1,2, Anne Marie Valente1,2, Laith Alshawabkeh3, Susan Cheng2,4, Allison Bradley1, Eric B Rimm5,6,7, Michael J Landzberg1,2. 1. Department of Cardiology, Boston Children's Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, MA, USA. 2. Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, USA. 3. Division of Cardiovascular Medicine, Department of Medicine, University of California San Diego, 200 West Arbor Drive, San Diego, CA, USA. 4. Framingham Heart Study, 73 Mount Wayte Avenue, Suite 2, Framingham, MA, USA. 5. Department of Epidemiology, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue Boston, MA, USA. 6. Department of Nutrition, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue Boston, MA, USA. 7. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, USA.
Abstract
Aims: Despite the well-defined association of high-sensitivity hsCRP with cardiovascular outcomes in apparently healthy adults and those with acquired heart disease, the relevance of this inflammatory marker in adults with congenital heart disease (ACHD) remains unclear. We aimed to examine the clinical correlates and prognostic value of high-sensitivity C-reactive protein levels in ACHD. Methods and results: We conducted a prospective cohort study of (n = 707) outpatient ACHD (age 39 ± 14 years, 49% women), enrolled mainly at a referral centre, who had serum hsCRP measured in conjunction with a clinical assessment between 2012 and 2016. We analysed clinical correlates of hsCRP and its association with adverse events including the primary combined outcome of all-cause mortality or non-elective cardiovascular hospitalization. Higher hsCRP was strongly associated with measures of functional status including New York Heart Association class and peak V̇O2, and with comorbidities such as atrial arrhythmia. During average follow-up of 815 ± 536 days, 114 patients (16%) experienced the primary outcome, including 29 deaths. Having elevated hsCRP, in the highest (≥2.98 mg/L) compared with the lower three quartiles, conferred increased risk for the primary outcome [30.5% vs. 11.3%, adjusted hazard ratio (HR) = 2.00, 95% confidence interval (CI) 1.35-2.97; P = 0.0006] and all-cause mortality (11.9% vs. 1.5%, adjusted HR = 4.23, 95% CI 1.87-9.59; P = 0.0006). Elevated hsCRP was associated with adverse outcomes across ACHD subgroups and other patient characteristics. Conclusion: Adults with congenital heart disease with elevated hsCRP have not only worse functional status and exercise capacity, but also greater risk for death or non-elective cardiovascular hospitalization. Further study is warranted to characterize the role of inflammation in the pathophysiology of ACHD.
Aims: Despite the well-defined association of high-sensitivity hsCRP with cardiovascular outcomes in apparently healthy adults and those with acquired heart disease, the relevance of this inflammatory marker in adults with congenital heart disease (ACHD) remains unclear. We aimed to examine the clinical correlates and prognostic value of high-sensitivity C-reactive protein levels in ACHD. Methods and results: We conducted a prospective cohort study of (n = 707) outpatient ACHD (age 39 ± 14 years, 49% women), enrolled mainly at a referral centre, who had serum hsCRP measured in conjunction with a clinical assessment between 2012 and 2016. We analysed clinical correlates of hsCRP and its association with adverse events including the primary combined outcome of all-cause mortality or non-elective cardiovascular hospitalization. Higher hsCRP was strongly associated with measures of functional status including New York Heart Association class and peak V̇O2, and with comorbidities such as atrial arrhythmia. During average follow-up of 815 ± 536 days, 114 patients (16%) experienced the primary outcome, including 29 deaths. Having elevated hsCRP, in the highest (≥2.98 mg/L) compared with the lower three quartiles, conferred increased risk for the primary outcome [30.5% vs. 11.3%, adjusted hazard ratio (HR) = 2.00, 95% confidence interval (CI) 1.35-2.97; P = 0.0006] and all-cause mortality (11.9% vs. 1.5%, adjusted HR = 4.23, 95% CI 1.87-9.59; P = 0.0006). Elevated hsCRP was associated with adverse outcomes across ACHD subgroups and other patient characteristics. Conclusion: Adults with congenital heart disease with elevated hsCRP have not only worse functional status and exercise capacity, but also greater risk for death or non-elective cardiovascular hospitalization. Further study is warranted to characterize the role of inflammation in the pathophysiology of ACHD.
Authors: Jacques Genest; Ruth McPherson; Jiri Frohlich; Todd Anderson; Norm Campbell; André Carpentier; Patrick Couture; Robert Dufour; George Fodor; Gordon A Francis; Steven Grover; Milan Gupta; Robert A Hegele; David C Lau; Lawrence Leiter; Gary F Lewis; Eva Lonn; G B John Mancini; Dominic Ng; Glen J Pearson; Allan Sniderman; James A Stone; Ehud Ur Journal: Can J Cardiol Date: 2009-10 Impact factor: 5.223
Authors: W Koenig; M Sund; M Fröhlich; H G Fischer; H Löwel; A Döring; W L Hutchinson; M B Pepys Journal: Circulation Date: 1999-01-19 Impact factor: 29.690
Authors: Bonnie Ky; Benjamin French; Wayne C Levy; Nancy K Sweitzer; James C Fang; Alan H B Wu; Lee R Goldberg; Mariell Jessup; Thomas P Cappola Journal: Circ Heart Fail Date: 2012-02-23 Impact factor: 8.790
Authors: Vivan J M Baggen; Annemien E van den Bosch; Jannet A Eindhoven; Myrthe E Menting; Maarten Witsenburg; Judith A A E Cuypers; Eric Boersma; Jolien W Roos-Hesselink Journal: Heart Date: 2017-09-23 Impact factor: 5.994
Authors: Giancarlo Scognamiglio; Aleksander Kempny; Laura C Price; Rafael Alonso-Gonzalez; Philip Marino; Lorna Swan; Michele D' Alto; James Hooper; Michael A Gatzoulis; Konstantinos Dimopoulos; Stephen J Wort Journal: Heart Date: 2014-05-01 Impact factor: 5.994
Authors: Vivan J M Baggen; Annemien E van den Bosch; Jannet A Eindhoven; Anne-Rose W Schut; Judith A A E Cuypers; Maarten Witsenburg; Monique de Waart; Ron H N van Schaik; Felix Zijlstra; Eric Boersma; Jolien W Roos-Hesselink Journal: Circulation Date: 2016-11-03 Impact factor: 29.690
Authors: Susan G Lakoski; Mary Cushman; Michael Criqui; Tatjana Rundek; Roger S Blumenthal; Ralph B D'Agostino; David M Herrington Journal: Am Heart J Date: 2006-09 Impact factor: 4.749
Authors: Massimo F Piepoli; Arno W Hoes; Stefan Agewall; Christian Albus; Carlos Brotons; Alberico L Catapano; Marie-Therese Cooney; Ugo Corrà; Bernard Cosyns; Christi Deaton; Ian Graham; Michael Stephen Hall; F D Richard Hobbs; Maja-Lisa Løchen; Herbert Löllgen; Pedro Marques-Vidal; Joep Perk; Eva Prescott; Josep Redon; Dimitrios J Richter; Naveed Sattar; Yvo Smulders; Monica Tiberi; H Bart van der Worp; Ineke van Dis; W M Monique Verschuren; Simone Binno Journal: Eur Heart J Date: 2016-05-23 Impact factor: 29.983
Authors: Alexander R Opotowsky; Fernando Baraona; Justin Owumi; Brittani Loukas; Michael N Singh; Anne Marie Valente; Fred Wu; Susan Cheng; Gruschen Veldtman; Eric B Rimm; Michael J Landzberg Journal: J Am Heart Assoc Date: 2016-01-11 Impact factor: 5.501
Authors: Anita Saraf; Christine De Staercke; Ian Everitt; Alice Haouzi; Yi-An Ko; Staci Jennings; Jonathan H Kim; Fred H Rodriguez; Andreas P Kalogeropoulos; Arshed Quyyumi; Wendy Book Journal: Int J Cardiol Date: 2020-01-09 Impact factor: 4.164
Authors: Laurie W Geenen; Lucas Uchoa de Assis; Vivan J M Baggen; Jannet A Eindhoven; Judith A A E Cuypers; Eric Boersma; Jolien W Roos-Hesselink; Annemien E van den Bosch Journal: Int J Cardiol Heart Vasc Date: 2020-07-21
Authors: Miriam Michel; Karl-Otto Dubowy; Manuela Zlamy; Daniela Karall; Mark Gordian Adam; Andreas Entenmann; Markus Andreas Keller; Jakob Koch; Irena Odri Komazec; Ralf Geiger; Christina Salvador; Christian Niederwanger; Udo Müller; Sabine Scholl-Bürgi; Kai Thorsten Laser Journal: Ther Adv Chronic Dis Date: 2020-04-27 Impact factor: 5.091
Authors: Laurie W Geenen; Roderick W J van Grootel; Korhan Akman; Vivan J M Baggen; Myrthe E Menting; Jannet A Eindhoven; Judith A A E Cuypers; Eric Boersma; Annemien E van den Bosch; Jolien W Roos-Hesselink Journal: J Am Heart Assoc Date: 2019-08-21 Impact factor: 5.501
Authors: Matthew R Carazo; Meghan S Kolodziej; Elizabeth S DeWitt; Nadine A Kasparian; Jane W Newburger; Valeria E Duarte; Michael N Singh; Alexander R Opotowsky Journal: J Am Heart Assoc Date: 2020-04-28 Impact factor: 5.501
Authors: Laurie W Geenen; Vivan J M Baggen; Annemien E van den Bosch; Jannet A Eindhoven; Robert M Kauling; Judith A A E Cuypers; Jolien W Roos-Hesselink; Eric Boersma Journal: Heart Date: 2020-10-15 Impact factor: 5.994
Authors: Adam M Lubert; Tarek Alsaied; Joseph J Palermo; Nadeem Anwar; Elaine M Urbina; Nicole M Brown; Craig Alexander; Hassan Almeneisi; Fred Wu; Andrew R Leventhal; Nael Aldweib; Michael Mendelson; Alexander R Opotowsky Journal: J Am Heart Assoc Date: 2021-03-31 Impact factor: 5.501